This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ridker, P. M Search for Related Content PubMed Articles by Ridker, P. M Related Collections Related Article

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2008;28:1222.)
© 2008 American Heart Association, Inc.

Editorials

The Time for Cardiovascular Inflammation Reduction Trials Has Arrived

How Low to Go for hsCRP?

Paul M Ridker

From the Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to Dr Paul Ridker, Director, Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215. E-mail pridker@partners.org

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Inflammation is a major determinant of atherothrombosis, and based on more than a decade of consistent prospective epidemiological evidence, the inflammatory biomarker high-sensitivity C-reactive protein (hsCRP) is in clinical use an independent determinant of cardiovascular risk, even when levels of LDL-C are low.¹ Guidelines for use of hsCRP as an adjunct to global risk prediction were issued by the American Heart Association in 2003,² and risk algorithms incorporating hsCRP such as the Reynolds Risk Score have been developed and validated.³ Increased hsCRP levels not only predict future risk of myocardial infarction, stroke, and cardiovascular death, but are intimately associated with metabolic syndrome and incident diabetes.^4,5 As a result of interrelationships with insulin resistance, leptin, adiponectin, cytokine function, endothelial dysfunction, and impaired fibrinolysis, CRP has been hypothesized to present a common link in pathways connecting vascular inflammation, diabetes, and premature atherothrombosis.⁶ There appears to be an underlying genetic basis for these relationships; in a genome wide association study of more than 6000 women, unsuspected genetic determinants of CRP have been found that include polymorphism in the leptin receptor gene LEPR and in 2 loci that are more commonly considered genes associated with maturity onset diabetes of the young, GCKR and HNF1.⁷

See accompanying article on page 1385

Despite the consistency of these data, it remains controversial as to whether lowering CRP is a relevant therapeutic goal, and if so, how low hsCRP levels should go in clinical practice. In this issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Arima and . . . [Full Text of this Article]

Related Article:

High-Sensitivity C-Reactive Protein and Coronary Heart Disease in a General Population of Japanese: The Hisayama Study

Hisatomi Arima, Michiaki Kubo, Koji Yonemoto, Yasufumi Doi, Toshiharu Ninomiya, Yumihiro Tanizaki, Jun Hata, Kiyoshi Matsumura, Mitsuo Iida, and Yutaka Kiyohara
Arterioscler Thromb Vasc Biol 2008 28: 1385-1391. [Abstract] [Full Text] [PDF]

This article has been cited by other articles:

				P. M Ridker C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease Clin. Chem., February 1, 2009; 55(2): 209 - 215. [Full Text] [PDF]

				P. M Ridker, E. Danielson, F. A.H. Fonseca, J. Genest, A. M. Gotto Jr., J. J.P. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, et al. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein N. Engl. J. Med., November 20, 2008; 359(21): 2195 - 2207. [Abstract] [Full Text] [PDF]